Management of bone metastases in breast cancer
Author:
- 1 April 2005
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 6 (2) , 161-171
Abstract
Patients with advanced breast cancer who develop bone metastases suffer an ongoing risk of skeletal complications that can have a significant impact on their quality of life (QoL). These complications include bone pain, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy (HCM), a potentially life-threatening condition. Treatment options include radiotherapy to palliate bone pain and/ or prevent impending fracture, orthopedic surgery to prevent or repair fractures, analgesics, and bisphosphonates, which can significantly reduce the risk of skeletal complications and delay their onset. Of the known bisphosphonates, zoledronic acid is the most potent. Since its regulatory approval in the United States and Europe in 2001, zoledronic acid (4 mg by 15-minute infusion) has become widely used and has replaced pamidronate (90 mg by 2-hour infusion) as the standard of care for treating bone metastases from breast cancer and bone lesions from multiple myeloma. Zoledronic acid has also demonstrated significant long-term benefits in randomized trials in prostate cancer and other solid tumors, whereas other bisphosphonates have failed. In long-term, phase III clinical testing, zoledronic acid provided significant treatment benefits beyond those of pamidronate in patients with breast cancer and demonstrated a safety profile comparable with pamidronate. Therefore, zoledronic acid is now recommended from the first diagnosis of bone metastasis. Other intravenous bisphosphonates include clodronate and ibandronate. Both are approved in Europe, but their efficacy relative to pamidronate and zoledronic acid is not known.Keywords
This publication has 36 references indexed in Scilit:
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Bisphosphonate therapy in the oncology settingExpert Opinion on Emerging Drugs, 2003
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Advances in Supportive Care of Patients With Cancer and Bone Metastases: Nursing Implications of Zoledronic AcidClinical Journal of Oncology Nursing, 2003
- Percutaneous vertebroplasty: indications, contraindications, and techniqueBritish Journal of Radiology, 2003
- Radiotherapy-related fatigueCritical Reviews in Oncology/Hematology, 2002
- Bisphosphonates for breast cancer2002
- Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myelomaBritish Journal of Haematology, 2001
- Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including RasJournal of Bone and Mineral Research, 1998
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982